Monopar Therapeutics MNPR 深 沪
等待开盘 09-17 09:30:00 美东时间
57.00
+2.510
+4.61%
华盛通- 最 高58.94
- 今 开55.70
- 成交量 7.64万股
- 最 低 54.80
- 昨 收 54.49
- 总市值 3.52亿
- 52周最高 58.94
- 市盈率 静 --
- 换手率 1.24%
- 52周最低 4.50
- 委 比 -98.02%
- 总股本 617.00万
- 历史最高 240.00
- 量 比 2.56
- 振 幅 7.60%
- 历史最低 1.3695
- 每 手 1
- 风险率 12.38%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | Arete Research上调百度"买入"评级，目标价143美元；瑞银上调蔚来"买入"评级，目标价升至8.5美元
今日重点评级关注：HC Wainwright & Co.：维持Orion Energy Sys"买入"评级，目标价从2美元升至20美元；高盛：维持Amylyx Pharmaceuticals"买入"评级，目标价从10美元升至20美元
今天 10:15
Chardan Capital Maintains Buy on Monopar Therapeutics, Maintains $60 Price Target
Chardan Capital analyst Keay Nakae maintains Monopar Therapeutics (NASDAQ:MNPR) with a Buy and maintains $60 price target.
09-16 19:11
美股大行评级 | 潜在涨幅432.99%！维持"投机性买入"评级，Unicycive Therapeutics获机构升目标价至21美元
今日重点评级关注：Benchmark：维持Unicycive Therapeutics"投机性买入"评级，目标价从3美元升至21美元；Guggenheim：维持Amylyx Pharmaceuticals"买入"评级，目标价从17美元升至25美元
09-16 09:48
Monopar To Present 6-Year Data Showing Sustained Neurological Improvement With ALXN1840 in Wilson Disease On UWDRS Part II and III At ANA Annual Meeting
Monopar Therapeutics Inc. (NASDAQ:MNPR) announced that new data on the long-term neurological efficacy and safety of its investigational therapy ALXN1840 (tiomolybdate choline) for Wilson disease will be presented at the
09-14 20:15
Monopar to Present New Long-Term Neurological Efficacy and Safety Data for ALXN1840 in Wilson Disease at the 150th American Neurological Association Annual Meeting
Monopar Therapeutics announced new long-term neurological efficacy and safety data for ALXN1840 in Wilson disease, presented at the 150th ANA Annual Meeting. The analysis included 255 patients for efficacy and 266 for safety, with a median treatment duration of 2.6 years. Key findings: sustained neurological improvement over 6 years, crossover benefit for patients switching from standard of care, significant psychiatric improvement, consistent be...
09-14 12:00
美股大行评级 | 潜在涨幅577.08%！Veritone获D. Boral Capital升目标价至26美元，维持"买入"评级
今日重点评级关注：D. Boral Capital：维持Veritone"买入"评级，目标价从6美元升至26美元；Guggenheim：维持Dianthus Therapeutics"买入"评级，目标价从92美元升至100美元
09-10 18:01
美股大行评级 | 潜在涨幅403.28%！瑞杰金融首予Kalaris Therapeutics"强烈买入"评级，目标价23美元
今日重点评级关注：花旗：维持Ionis Pharmaceuticals"买入"评级，目标价从69美元升至84美元；Melius Research：上调康明斯评级至"买入"，目标价500美元
09-04 09:49
Monopar Announces Abstract Accepted with Distinction for Oral and Poster Presentations at the Upcoming American Neurological Association 2025 Annual Meeting
Monopar Therapeutics Inc. announced that its research on ALXN1840 for Wilson disease has been selected as a distinguished abstract for both oral and poster presentations at the 150th ANA Annual Meeting. The study highlights long-term neurological benefits in patients and will be presented by Matthew Lorincz, M.D., Ph.D. from the University of Michigan. Additionally, Monopar is developing radiopharmaceutical programs for advanced cancer treatment ...
09-03 12:00
Monopar Therapeutics files $300M mixed securities shelf
Monopar Therapeutics (NASDAQ:MNPR) filed $300 million mixed securities shelf. Filing More on Monopar Therapeutics Seeking Alpha’s Quant Rating on Monopar Therapeutics Historical earnings data for Mono...
08-30 04:52
